Sort   by:  
 Page size 
UnknownCD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma.
Not available
S-EPMC7934939 | biostudies-literature
UnknownToxicities Associated With Metformin/Ritonavir Combination Treatment in Relapsed/Refractory Multiple Myeloma.
Not available
S-EPMC7541704 | biostudies-literature
UnknownLeveraging IFNγ/CD38 regulation to unmask and target leukemia stem cells in acute myelogenous leukemia.
Not available
S-EPMC10002674 | biostudies-literature
UnknownDaratumumab induces mechanisms of immune activation through CD38+ NK cell targeting.
Not available
S-EPMC7572537 | biostudies-literature
UnknownRepurposing leflunomide for relapsed/refractory multiple myeloma: a phase 1 study.
Not available
S-EPMC7384948 | biostudies-literature
UnknownPhase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BCNU, Etoposide, Cytarabine, and Melphalan for Non-Hodgkin Lymphoma: The Role of Histology.
Not available
S-EPMC5646666 | biostudies-literature
UnknownProteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects.
Not available
S-EPMC11744858 | biostudies-literature
UnknownPatient perspectives on symptoms, health-related quality of life, and treatment experience associated with relapsed/refractory multiple myeloma.
Not available
S-EPMC9135799 | biostudies-literature
UnknownIdentifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64-labeled daratumumab.
Not available
S-EPMC7594407 | biostudies-literature
UnknownTBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.
Not available
S-EPMC4451173 | biostudies-literature
Sort   by:  
 Page size